Investment Rating - The report does not explicitly state an investment rating for the small nucleic acid industry Core Insights - Small nucleic acid drugs have transitioned from technical validation to commercial realization, with projected sales of approximately $3.1 billion for ASO and $4.2 billion for siRNA by 2025 [3] - The development paths of ASO and siRNA are shaped by their mechanistic differences, with ASO utilizing a single-strand structure for direct delivery into target cells, while siRNA relies on carrier systems for effective delivery due to its larger size and strong negative charge [3] - Continuous evolution in chemical modifications and delivery platforms has improved the stability, targeting, safety, and convenience of small nucleic acid drugs, expanding their application from rare diseases to chronic conditions [3] - Current advancements in liver-targeting technologies are paving the way for the next phase of delivery to extrahepatic tissues, with future valuations of small nucleic acid companies focusing on platform capabilities and expansion into chronic disease treatments [3] Summary by Sections Small Nucleic Acids Unlock Gene Expression Regulation - Small nucleic acid drugs can target previously undruggable proteins by intervening at the gene expression level, significantly broadening the potential therapeutic targets [9][11] Pathways to Small Nucleic Acid Drug Development - The report outlines the dual pathways of ASO and siRNA, highlighting their distinct mechanisms and therapeutic applications [12][30] Mechanistic Differences: ASO vs. siRNA - ASO employs RNase H-mediated degradation and splicing regulation to inhibit protein expression, while siRNA utilizes the RISC mechanism for mRNA degradation [20][26] Chemical Modifications and Stability - The report details the evolution of chemical modifications across four generations, enhancing the stability and specificity of ASO and siRNA [32][36] Delivery Breakthroughs - The challenges of delivering small nucleic acids across cellular barriers are discussed, emphasizing the need for effective delivery systems [40][44] Safety Optimization - Innovations in toxicity management for ASO and siRNA are crucial for supporting long-term use and chronic disease management [62][64] Commercialization and Boundary Expansion - The report emphasizes the transition from liver-targeted therapies to exploring delivery strategies for other tissues, indicating a strategic shift in the industry [60][61]

Investment Rating - The report indicates a positive investment outlook for the nucleic acid drug industry, anticipating it to become the third major category of drugs, driven by technological innovation and increased capital investment [5]. Core Insights - Nucleic acid drugs are emerging as a new therapeutic approach with high efficiency and low toxicity, particularly in rare diseases, and are expanding into common diseases. The global market for nucleic acid drugs is rapidly growing, supported by expanded indications, policy backing, and research collaborations [5]. - The nucleic acid drug market size grew from 18.816 billion RMB in 2019 to 155.828 billion RMB in 2023, with a compound annual growth rate (CAGR) of 69.64%. However, it is expected to decline to 117.545 billion RMB by 2028, with a negative CAGR of -3.82% [10]. - The industry is witnessing a shift from rare diseases to chronic diseases and tumors, with significant advancements in technology and delivery systems, including AI-assisted design and liver-targeted delivery [34][36][38]. Market Background - Nucleic acid drugs are defined as drugs that utilize nucleic acids to intervene in disease by regulating gene expression. They have shown potential in treating metabolic diseases, genetic disorders, and cancers [6]. - The exploration of nucleic acid drugs began in 1978, with the first commercial product, Vitravene, launched in 1998. The market has since evolved, with significant developments in RNA therapies [7][8]. Market Status - The nucleic acid drug market is primarily focused on rare diseases but is gradually expanding to common diseases. The demand for treatment is urgent due to the high prevalence of rare diseases, with over 7,000 known globally [15]. - Capital investment in the nucleic acid sector has increased, with 23 financing events reported in 2024, totaling nearly 3 billion RMB. This funding supports the development of innovative drug delivery systems and clinical trials [12]. Market Competition - The competitive landscape features a tiered structure, with leading companies such as Saint No Biopharma and Hegia Biopharma in the first tier, followed by companies like Rebio and Haobo Pharmaceutical in the second tier [19][20]. - The report highlights ten recommended brands in the nucleic acid drug space, including Rebio, Watson Biopharma, and Saint No Biopharma, each with unique strengths and challenges in their product pipelines [22][23][24]. Development Trends - Technological breakthroughs in liver-targeted delivery and AI design are driving innovation in the nucleic acid drug industry, with expectations that over 50% of the pipeline will utilize these advancements by 2030 [34]. - The commercialization of nucleic acid drugs is accelerating through licensing agreements and healthcare payment reforms, enhancing drug accessibility and market growth [35]. - The industry is expanding its focus from rare diseases to chronic diseases and tumors, with significant research and clinical trials underway for conditions such as hypertension and Alzheimer's disease [38].

Core Insights - The report from Huazhong Securities highlights breakthroughs in small nucleic acid technology and its application in rare diseases, cardiovascular diseases, significant metabolic areas, CNS, and even oncology, indicating a growing investment opportunity in the siRNA sector [1] Group 1: Key Events - Novartis plans a major investment in small nucleic acids by 2025, with three business development (BD) transactions and a $12 billion acquisition, reflecting significant industry impact [1] - Novartis's product Inclisiran achieved $555 million in sales in the first half of 2025, a 66% year-on-year increase, and its Swiss base received an $80 million investment to expand siRNA production [1] - Domestic company Bewang Pharmaceutical's $5 billion out-licensing deal with Novartis sets a record for non-oncology BD transaction amounts [1] Group 2: Technological Advancements - Delivery technology is advancing from liver-targeting to cross-brain and lung-targeting, indicating breakthroughs in extrahepatic targeting [2] - The range of indications is expanding from rare diseases and cardiovascular conditions to significant metabolic areas, CNS, and oncology [2] Group 3: Drug Target Layout - Established targets include Inclisiran (PCSK9), which opened the siRNA application in cardiovascular fields, with emerging targets like INHBE and ALK7 showing promising initial data in obesity [3] - New targets such as ApoC3, Lpa, and ANGPTL3 are becoming standard for drug companies in lipid regulation treatments, while AGT and FXI are deepening applications in hypertension and thrombotic diseases [3] - The siRNA application scope is continuously expanding with new developments in diseases related to complement and kidney conditions [3]

Summary of Key Points from Conference Call Records Industry Overview - The small nucleic acid drug industry is experiencing rapid growth, with significant advancements expected in 2026, particularly in delivery technologies for non-liver areas such as the nervous system and fat [1][2] - The collaboration between Novartis and Alnylam on Inclisiran has resulted in the first small interfering RNA (siRNA) product with annual sales exceeding $1 billion, indicating strong market potential for small nucleic acid drugs [1][6] Core Insights and Arguments - Alnylam's upcoming key data on its nervous system delivery pipeline and Ionis's APOE3 drug is anticipated to validate the commercial potential of small nucleic acid drugs in chronic disease markets [1][2] - Capital and technological breakthroughs are driving more first-tier market companies to go public, with companies like Rebio, Bowang, and Elite Bio already in the IPO queue [1][2] - International clinical data from companies like LPA, GBTL3, and HPV are expected to catalyze further development in the small nucleic acid sector [1][2] Company-Specific Developments - **Rebio**: Focused on a major product, coagulation factor XI, with a market potential estimated to reach $10 billion, half of which is expected from atrial fibrillation indications. The company plans to co-develop this product [1][9] - **Yuekang Pharmaceutical**: Actively expanding in the small nucleic acid field with several pipelines obtaining IND approvals in both China and the U.S. The company anticipates significant sales growth in 2027 [1][10] - **Frontier Bio**: Has a promising product targeting IgA nephropathy, with plans to submit a dual-target IND application in 2026 [1][11] - **Bitbio and Fuyuan Pharmaceutical**: Both companies are making strides in the small nucleic acid space, with Bitbio focusing on differentiated molecular design and Fuyuan covering a broad patent and pipeline landscape [1][12] Technological and Collaborative Advances - Chinese companies have established over $2 billion in platform collaborations with international giants, indicating strong capabilities in small nucleic acid technology and patent protection [1][13] - Continuous optimization of small nucleic acid modification and delivery technologies is expected to further propel industry growth [1][13] Additional Important Insights - The small nucleic acid drugs are categorized into ASO (antisense oligonucleotides) and siRNA, each with distinct mechanisms and advantages, such as longer half-lives and lower immunogenicity [1][3][4] - Key stages in the development of small nucleic acid drugs include sequence screening, chemical modification, and delivery methods, with a focus on liver-targeted delivery and exploration of non-liver delivery methods [1][5]

Summary of Key Points from the Conference Call on Small Nucleic Acid Drugs Industry Overview - The small nucleic acid drug market has expanded from rare diseases to chronic diseases such as metabolic and cardiovascular conditions, with significant growth in sales of PCSK9 inhibitors like Inclisiran, driven by advancements in liver delivery technology [1][4][11] - The market is expected to see explosive growth in 2025, with increased data releases and potential business development (BD) activities [2] Core Insights and Arguments - Small nucleic acid drugs target mRNA, allowing for interference with gene expression upstream, overcoming limitations of traditional small molecule inhibitors and protein antibody drugs [1][5] - The siRNA technology, particularly using GalNAc for liver delivery, has shown high efficiency and selectivity, with Inclisiran projected to reach $750 million in sales in 2024 and over $1 billion in 2025 [1][11] - Recent collaborations in the small nucleic acid field, such as the $4.2 billion agreement between BGI and Novartis, highlight the growing interest and value of early clinical pipeline products [1][12] Market Dynamics - The pricing of small nucleic acid drugs is high, with initial treatment costs around $700,000, followed by annual costs of approximately $350,000, reflecting high clinical demand and the rarity of diseases treated [9] - The market is segmented into metabolic and cardiovascular-related areas, with established targets like PCSK9, Lpa, and ApoC3 showing high drugability [22] Competitive Landscape - Leading companies in the small nucleic acid space include Adaltum in the SRA field and Ionis in the ASO field, with ongoing research into delivery mechanisms [30] - Domestic companies such as Hengrui Medicine and Shiyao Group are actively developing SRA projects in chronic hepatitis B, hypertension, and dyslipidemia [31] Challenges and Opportunities - The small nucleic acid drug development faces challenges in stability and delivery efficiency, necessitating chemical modifications and innovative delivery technologies [14][15] - New ligands, such as lipid molecules and specific peptides, are being explored to enhance targeted delivery of small nucleic acid drugs [20] Future Trends - The dual-target combination therapy strategy, such as coupling PCSK9 with ApoC3, shows promising potential for improved treatment outcomes [28] - The anticipated IPOs of high-quality small nucleic acid biotech companies in Hong Kong by 2026 are expected to boost market sentiment and investment in the sector [2][33] Conclusion - The small nucleic acid drug industry is poised for significant growth, driven by technological advancements, strategic collaborations, and a robust pipeline of innovative therapies targeting chronic diseases. The landscape is evolving with new entrants and increased competition, particularly in the domestic market, which is expected to gain international traction through strategic partnerships and collaborations.

Investment Rating - The report maintains a "Buy" rating for the small nucleic acid sector, anticipating significant catalysts by 2026 [5]. Core Views - The report emphasizes three main investment themes for 2026: innovation, international expansion, and turnaround opportunities. It suggests focusing on innovative drugs, biotech companies that have gone global, and supply chain strategies [2][21]. - The small nucleic acid therapy market is expected to experience substantial growth, with FDA-approved drugs like Inclisiran and Vutrisiran projected to reach sales of $754 million and $971 million respectively by 2024 [3][16]. Summary by Sections 1. Small Nucleic Acid Market Outlook - The report highlights the commercial growth potential of small nucleic acid therapies, with significant sales forecasts for drugs like Inclisiran and Vutrisiran, and a projected market size of $30 billion for Novartis's xRNA therapies [3][16]. - The business development (BD) trend for siRNA therapies is improving, with notable deals such as a $4.165 billion agreement with Novartis [3][20]. - Clinical catalysts are expected, with Arrowhead's ARO-DIMER-PA set to announce trial results in H2 2026 [4][20]. - Increased capital recognition is noted, with companies like Rebio Biotech preparing for IPOs, indicating a positive market sentiment [4][20]. 2. Market Review and Trends - The report reviews the recent performance of the pharmaceutical sector, noting a 1.04% decline in the A-share pharmaceutical index, underperforming compared to the ChiNext and CSI 300 indices [24][28]. - The overall trading volume in the pharmaceutical sector was 423.35 billion yuan, accounting for 4.38% of the total market, below the historical average of 7.13% [43][24]. - The report identifies the best-performing sub-sector as medical services II, while the worst was pharmaceutical commerce II [35][38]. 3. Investment Recommendations - The report recommends focusing on high-quality siRNA companies in China, such as Frontier Biotech, Yuyuan Pharmaceutical, and others, as they are positioned for rapid development in the small nucleic acid space [7][21]. - It suggests monitoring the clinical progress of various siRNA drugs in development, particularly those targeting metabolic diseases [22][21].

Group 1 - The core viewpoint of the article highlights the positive impact of the Federal Reserve's interest rate cut on the Hong Kong stock market, particularly in the biotechnology sector, which is expected to see valuation recovery due to improved liquidity conditions [1][2] - The article discusses the ongoing optimization of the policy environment in the pharmaceutical industry, emphasizing the shift from price competition to value competition, supported by innovative payment models and regulatory measures [1][2] - The introduction of the Hang Seng Biotechnology Index futures is seen as a significant step in enhancing the investment ecosystem for the biotechnology sector, attracting long-term capital and stabilizing market expectations [3] Group 2 - The biotechnology sector is positioned for structural allocation opportunities due to its current low valuation levels and favorable policy support, with significant inflows from southbound capital [4] - The article notes that small nucleic acid drugs are emerging as a core area for innovation, with recent breakthroughs in delivery technology expanding their therapeutic applications [2] - The performance of leading biopharmaceutical companies and the increase in overseas collaborations indicate a strengthening of the industry's fundamentals and confidence [1][2]

Summary of Expert Call on Small Nucleic Acid Drugs in China Industry Overview - **Industry Focus**: Small nucleic acid drugs in China, specifically RNA drugs, including siRNA and ASO [1][6] - **Market Potential**: Significant opportunities in chronic diseases and liver-related conditions due to lower technological barriers and rapid adoption of siRNA therapies [2][8] Key Insights Market Potential and Applications - **siRNA Advantages**: Demonstrates clear efficacy in metabolic diseases, particularly hyperlipidemia and hepatitis B, compared to existing treatments [2][9] - **ASO Preference**: Generally preferred for cancer, CNS disorders, and genetic diseases where siRNA efficacy is limited [2][7] - **Emerging Opportunities**: Rare diseases present significant opportunities in China due to the large population base, with many companies exploring these indications [8] Delivery Systems - **GalNAc Dominance**: The most popular delivery system in China is liver-targeted GalNAc, originally developed by Alnylam, with domestic companies working on structural modifications for proprietary IP [3][10] - **Extrahepatic Delivery**: Arrowhead leads globally in extrahepatic delivery, while Chinese firms are still adapting existing designs [3][10] Safety and Efficacy - **Safety Profiles**: siRNA drugs generally show a favorable safety profile, but chemical modifications for stability may introduce renal toxicity [2][13] - **Technological Modifications**: ASO drugs require higher dosages and nucleic entry, raising risks of side effects, necessitating further technological advancements [2][13] Manufacturing Challenges - **Cost of Production**: Manufacturing small nucleic acid drugs is more expensive than small molecule drugs but less costly than antibodies, with a reliance on chemical synthesis [14] Oncology Potential - **Limitations in Oncology**: siRNA faces challenges in oncology due to the need for penetration of the tumor microenvironment, while ASO may offer greater potential by targeting telomerase [15] Risks and Challenges - **Industry Risks**: Potential risks include price cuts from GPO programs, intensified competition, lower-than-expected innovative drug prices, slower consumption recovery, stricter regulations, and geopolitical tensions impacting operations [17] Conclusion - The small nucleic acid drug market in China is poised for growth, particularly in chronic diseases and rare conditions, with ongoing advancements in delivery systems and safety profiles. However, challenges in manufacturing, safety, and competition remain critical considerations for investors and companies in this sector.

Summary of Key Points from the Conference Call on Small Nucleic Acid Drugs Industry Overview - The discussion centers around the small nucleic acid drug industry, highlighting its advantages over traditional drug platforms and the potential for various applications in treating diseases. Core Insights and Arguments 1. **Efficacy and Mechanism**: Small nucleic acid drugs can reduce protein expression levels by over 80%-90%, significantly outperforming small molecule and antibody drugs, which only lower activity or clear existing proteins [2][5][8] 2. **Long-lasting Effects**: Some small nucleic acid therapies require administration only once every six months, showcasing their long-lasting effects and low resistance development [2][5] 3. **Delivery Technologies**: The Golang liver delivery technology is currently the mainstream method but is limited to liver applications. New strategies involving peptide and antibody modifications aim to expand delivery beyond the liver [3][4] 4. **Multi-target Strategies**: The potential of multi-target strategies in drug development is significant, as demonstrated by Novartis' Inclisiran, which generated $790 million in revenue in the first three quarters of the year [5][8] 5. **Emerging Markets**: There is a growing market for small nucleic acid drugs in obesity treatment, with drugs like GPS-75 showing promise in altering the current weight loss market dynamics [9][20] 6. **Rare Diseases and CNS Applications**: Small nucleic acid drugs show potential in treating rare diseases and central nervous system disorders, with Novartis' acquisition of RVDP technology indicating strong confidence in muscle disease treatments [8][11] 7. **Challenges in Delivery**: The complexity of delivery systems poses significant barriers to entry for new companies, as effective delivery tools are crucial for the success of small nucleic acid therapies [12][22] 8. **Chemical Modifications**: Chemical modifications are essential for enhancing the stability and bioavailability of small nucleic acids, although current methods do not create significant barriers to entry [13][14] 9. **Market Potential**: The market for small nucleic acid drugs in treating cardiovascular diseases is substantial, as indicated by the $12 billion acquisition of a muscle treatment drug by Novartis [10][22] Other Important Insights 1. **Clinical Trials and Data**: Ongoing clinical trials, such as Wave 007, are showing promising results in weight loss applications, indicating a trend towards combining small nucleic acid drugs with existing therapies like GLP-1 [20][21] 2. **Regulatory and Safety Considerations**: The design of small nucleic acid sequences must consider potential off-target effects, necessitating thorough testing to ensure safety [18][25] 3. **Domestic Innovations**: Domestic companies like Shengyin, Bowang, and Ruibo are making significant strides in small nucleic acid research, with collaborations and innovations that enhance their market positions [28] This summary encapsulates the key points discussed in the conference call, providing a comprehensive overview of the small nucleic acid drug industry, its current state, and future potential.

Core Insights - The small nucleic acid drug market is entering a high-growth phase, driven by advancements in delivery technologies like GalNAc, which have enabled commercialization of liver-targeted drugs and expansion into common disease areas such as cardiovascular and central nervous system disorders [1][2]. Group 1: Industry Overview - Small nucleic acid drugs represent the third major class of drugs, including ASO and siRNA, with strong targeting capabilities and long-lasting effects, providing breakthroughs for traditionally non-druggable targets [1]. - The global small nucleic acid drug market is projected to grow from approximately $6.2 billion in 2024 to $46.7 billion by 2033, with a compound annual growth rate (CAGR) of 25% [2]. - The industry is characterized by a "one strong, many strong" structure, with leading companies like Alnylam, Ionis, and Arrowhead at the forefront of technology and pipeline development [2]. Group 2: Company Performance - Alnylam has established itself as the global leader in the siRNA field, leveraging its pioneering GalNAc liver-targeting delivery technology, which has set industry benchmarks [3]. - Since entering the commercialization phase in 2018, Alnylam has seen significant revenue growth, with total revenue reaching $2.617 billion in the first three quarters of 2025, a 58% year-on-year increase, and product net revenue of $1.992 billion, up 67% [3]. - The company continues to enhance its platform technology and expand its pipeline, with multiple cardiovascular, CNS, and rare disease drugs in clinical stages, which are expected to broaden its therapeutic indications [3]. Group 3: Investment Opportunities - Companies with leading advantages in small nucleic acid drug platform technologies and differentiated competitive positioning in target layouts are recommended for investment consideration, including Yuyuan Pharmaceutical, Fuyuan Pharmaceutical, Frontier Biotech, Shiyao Group, and Hengrui Medicine [4].